Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Safety considerations for new vaccine development.

S S Ellenberg1

  • 1Office of Biostatistics and Epidemiology, Center for Biologics Evaluation and Research, US Food and Drug Administration, MD, USA. ellenberg@cber.fda.gov

Pharmacoepidemiology and Drug Safety
|January 23, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effect of testosterone treatment on the trabecular bone score in older men with low serum testosterone.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2021
Same author

Clinical Trials in Veterinary Medicine: A New Era Brings New Challenges.

Journal of veterinary internal medicine·2017
Same author

Surrogate endpoints: the debate goes on.

Pharmacoepidemiology and drug safety·2002
Same author

The epidemiology of fatalities reported to the vaccine adverse event reporting system 1990-1997.

Pharmacoepidemiology and drug safety·2002
Same author

Evaluating the safety of combination vaccines.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2001
Same author

Considerations in the evaluation of surrogate endpoints in clinical trials. summary of a National Institutes of Health workshop.

Controlled clinical trials·2001
Same journal

Effectiveness of Metformin in Preventing Colorectal Cancer Among Japanese Patients With Type 2 Diabetes: A Target Trial Emulation.

Pharmacoepidemiology and drug safety·2026
Same journal

Trends in Pharmacist-Prescribed Dispensing Records of HIV Pre-Exposure (2020-2025) and Post-Exposure Prophylaxis (2020-2024) in Brazil: A Time Series Analysis.

Pharmacoepidemiology and drug safety·2026
Same journal

French Consumption of Methylphenidate in Primary Care From 2016 to 2023, Impact of Prescribing Policy Changes-A Time-Series Analysis.

Pharmacoepidemiology and drug safety·2026
Same journal

Uptake and Use of Biologic Therapies in Paediatric Immune-Mediated Inflammatory Diseases: An Australian Population-Based Study.

Pharmacoepidemiology and drug safety·2026
Same journal

Comparative Effectiveness of Oral Fluoropyrimidines Versus FOLFOX as Adjuvant Therapy for Stage III Colon Cancer: A Retrospective Cohort Study Using Overlap-Weighted Restricted Mean Survival Time Analysis.

Pharmacoepidemiology and drug safety·2026
Same journal

Association Between EGFR-TKI-Associated Skin Rash and Recorded Mortality in Non-Small Cell Lung Cancer: A Real-World Analysis Accounting for Immortal Time Bias.

Pharmacoepidemiology and drug safety·2026
See all related articles

Increasing vaccine trial sizes can improve safety detection. Larger clinical trials help identify rare adverse events, boosting vaccine confidence and reducing risks before widespread use.

Area of Science:

  • Immunology
  • Vaccinology
  • Public Health

Background:

  • Vaccines are crucial for public health but can have rare, serious adverse events.
  • Distinguishing coincidental health events from vaccine-induced ones is challenging post-licensure.

Purpose of the Study:

  • To highlight the limitations of current vaccine clinical trial sizes in detecting rare adverse events.
  • To advocate for larger clinical trials to enhance pre-licensure vaccine safety assessment.

Main Methods:

  • The study discusses the challenges in causality assessment of adverse events following vaccination.
  • It emphasizes the statistical limitations of small clinical trials for rare event detection.

Main Results:

  • Current clinical trials are often too small to identify rare but serious vaccine side effects.

Related Experiment Videos

  • Larger trials would provide more robust safety data before population-wide vaccine exposure.

    • Conclusions:

    • Increasing vaccine clinical trial size is essential for comprehensive safety evaluation.
    • Enhanced pre-licensure safety data increases public confidence and minimizes risks of severe vaccine-related injuries.